← back to search

Karin E. Smedby

Karolinska University Hospital · SE
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, and Immunodeficiency and Autoimmune Disorders.
h-index
65
citations
14,113
works
441
NIH funding
primary concept
Medicine
email

Recent publications

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.
2026cited by 1position: contributordoi
Clonal hematopoiesis of indeterminate potential and risk of immune thrombocytopenia
Journal of Internal Medicine 2025cited by 5position: contributordoi
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
Leukemia 2025cited by 1position: middledoi
Supplementary Table S3 from Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies
2025cited by 0position: contributordoi
Supplementary Methods S1 from Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies
2025cited by 0position: contributordoi
Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial.
2025cited by 0position: contributordoi
Supplementary Table S1 from Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies
2025cited by 0position: contributordoi
Supplementary Table S2 from Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies
2025cited by 0position: contributordoi
Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases
Journal of Internal Medicine 2024cited by 21position: contributordoi
Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases
Journal of Internal Medicine 2024cited by 20position: middledoi
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
Blood 2024cited by 19position: middledoi
Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma.
2024cited by 8position: contributordoi
Potential for Cure by Stage across the Cancer Spectrum in the United States.
2024cited by 4position: contributordoi
Health-related quality of life and supportive care needs in young adult cancer survivors-a longitudinal population-based study.
2024cited by 0position: contributordoi
Table S1 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Table S2 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Figure S2 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Figure S1 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Data from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Figure S2 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Table S1 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Figure S1 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Table S2 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Data from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Figure S3 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
Figure S3 from Potential for Cure by Stage across the Cancer Spectrum in the United States
2024cited by 0position: contributordoi
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma
Journal of Clinical Oncology 2023cited by 45position: middledoi
Novel precision medicine approaches and treatment strategies in hematological malignancies
Journal of Internal Medicine 2023cited by 44position: lastdoi
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
2023cited by 35position: contributordoi
Novel precision medicine approaches and treatment strategies in hematological malignancies.
2023cited by 34position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 37 papers (2021–2025)Ingrid Glimelius · Uppsala University16 papers (2023–2025)Nathaniel Rothman · Cancer Genetics (United States)15 papers (2023–2025)Anna E. Coghill · National Cancer Institute15 papers (2023–2025)Denise L. Doolan · The University of Queensland15 papers (2023–2025)Ruth M. Pfeiffer · United States Department of Health and Human Services15 papers (2023–2025)Cheng-Ping Wang · National Taiwan University15 papers (2023–2025)Yomani D. Sarathkumara · The University of Queensland15 papers (2023–2025)Zhiwei Liu · Nanjing Medical University15 papers (2023–2025)Jaap M. Middeldorp · Radboud University Nijmegen15 papers (2023–2025)Qing Lan · Division of Cancer Epidemiology and Genetics15 papers (2023–2025) · 15 papers (2023–2025)Henrik Hjalgrim · Cancer Institute (WIA)15 papers (2023–2025)Ilona Argirion · Michigan Medicine15 papers (2023–2025)Carla Proietti · The University of Queensland15 papers (2023–2025)Yin-Chu Chien · Genomics Research Center, Academia Sinica15 papers (2023–2025)Chien-Jen Chen · Deleted Institution15 papers (2023–2025)Wan-Lun Hsu · Fu Jen Catholic University15 papers (2023–2025)Sam M. Mbulaiteye · Department of Health and Human Services15 papers (2023–2025)Allan Hildesheim · Oldham Council15 papers (2023–2025)